Horvath, Dennis, Temperton, Nigel J., Mayora-Neto, Martin, da Costa, Kelly, Cantoni, Diego, Horlacher, Reinhold, Günther, Armin, Brosig, Alexander, Morath, Jenny, Jakobs, Barbara, and others. (2023) Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice. Scientific Reports, 13 (1). Article Number 4648. ISSN 2045-2322. (doi:10.1038/s41598-023-31198-3) (KAR id:100557)
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Download this file (PDF/1MB) |
Preview |
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://doi.org/10.1038/s41598-023-31198-3 |
Abstract
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variants of the virus. This may ultimately only be possible through induction of potent and long-lasting immune responses in the nasopharyngeal tract, the initial entry site of SARS-CoV-2. To this end, we have designed a vaccine based on recombinantly expressed receptor binding domain (RBD) of SARS-CoV-2, fused to the C-terminus of C. perfringens enterotoxin, which is known to target Claudin-4, a matrix molecule highly expressed on mucosal microfold (M) cells of the nasal and bronchial-associated lymphoid tissues. To further enhance immune responses, the vaccine was adjuvanted with a novel toll-like receptor 3/RIG-I agonist (Riboxxim™), consisting of synthetic short double stranded RNA. Intranasal prime-boost immunization of mice induced robust mucosal and systemic anti-SARS-CoV-2 neutralizing antibody responses against SARS-CoV-2 strains Wuhan-Hu-1, and several variants (B.1.351/beta, B.1.1.7/alpha, B.1.617.2/delta), as well as systemic T-cell responses. A combination vaccine with M-cell targeted recombinant HA1 from an H1N1 G4 influenza strain also induced mucosal and systemic antibodies against influenza. Taken together, the data show that development of an intranasal SARS-CoV-2 vaccine based on recombinant RBD adjuvanted with a TLR3 agonist is feasible, also as a combination vaccine against influenza.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.1038/s41598-023-31198-3 |
Uncontrolled keywords: | Gastric Mucosa, Animals, Humans, Mice, Clostridium perfringens, Influenza Vaccines, Adjuvants, Immunologic, Antibodies, Viral, Adjuvants, Pharmaceutic, Toll-Like Receptor 3, Influenza, Human, Influenza A Virus, H1N1 Subtype, Antibodies, Neutralizing, COVID-19, SARS-CoV-2, COVID-19 Vaccines, M Cells |
Subjects: | Q Science > QR Microbiology > QR355 Virology |
Divisions: | Divisions > Division of Natural Sciences > Medway School of Pharmacy |
Funders: |
Wellcome Trust (https://ror.org/029chgv08)
UK Research and Innovation (https://ror.org/001aqnf71) Bill & Melinda Gates Foundation (https://ror.org/0456r8d26) Deutsche Forschungsgemeinschaft (https://ror.org/018mejw64) |
Depositing User: | Nigel Temperton |
Date Deposited: | 21 Mar 2023 21:53 UTC |
Last Modified: | 04 Mar 2024 16:21 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/100557 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):